Bharat Parenterals Reports Record Sales Amid Significant Profit Declines in March 2025

Bharat Parenterals, a small-cap player in the Pharmaceuticals & Biotechnology sector, has released its financial results for the quarter ending March 2025. The company reported net sales of Rs 103.98 crore, reflecting a significant year-on-year growth of 53.32%. This figure marks the highest sales recorded in the last five quarters, indicating a positive near-term sales trend. However, the financial results also reveal challenges for Bharat Parenterals. The Profit Before Tax (PBT) stood at Rs -10.23 crore, showing a notable decline of 155.75% year-on-year. Similarly, the Profit After Tax (PAT) was reported at Rs -4.73 crore, which represents a drastic fall of 1476.7% compared to the previous year. Additionally, the interest expense reached its highest level in the last five quarters at Rs 3.94 crore, reflecting an increase of 18.32% quarter-on-quarter, suggesting a rise in borrowing costs. In light of these developments, Bharat Parenterals has experienced adjustments in its evaluation, with its score improving from -10 to -7 over the past three months. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.